OVARIAN UNDIFFERENTIATED CARCINOMA

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…

This study tests whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemo. About 582 women took part.…

This phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal was…

This study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cance…

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This study tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned after standard therapy. It uses a patient's own stem cells to deliver a modified measles virus directly into the abdomen, aiming to kill cancer cells. The trial involves 34 partic…